{"id":"73c31de28448","type":"article","url":"https://hartvaat.nl/2020/09/01/2020-acc-expert-consensus-nieuwe-therapieen-voor-cv-risicoreductie-bij-diabetes-/","title":"2020 ACC Expert Consensus: nieuwe therapieën voor CV-risicoreductie bij diabetes type 2","title_en":"2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2020.05.037","source_url":"https://doi.org/10.1016/j.jacc.2020.05.037","authors":["Sandeep R Das","Brendan M Everett","Kim K Birtcher","Jenifer M Brown","James L Januzzi","Rita R Kalyani","Mikhail Kosiborod","Melissa Magwire","Pamela B Morris","Joshua J Neumiller","Laurence S Sperling"],"significance":9,"published":"2020-09-01","source_date":"2020-09-01","image":"","kennis":["https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"The 2020 ACC Expert Consensus updated the decision pathway for SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes, integrating evidence from DAPA-HF, CREDENCE, and other contemporary trials to guide agent selection based on predominant cardiovascular or renal comorbidity.","created":"2026-07-03T10:28:44Z","updated":"2026-07-03T13:27:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"ACC 2020 geactualiseerde expert consensus over SGLT2-remmers en GLP-1-agonisten voor CV-risicoreductie bij diabetes type 2. Integreert DAPA-HF en CREDENCE.","abstract_original":""}